SML2892
LY2584702 tosylate
≥98% (HPLC)
别名:
4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine, 4-methylbenzenesulfonate (1:1), LY 2584702 tosylate, LY 2779964, LY-2584702 tosylate, LY-2779964, LY2779964, LYS6K2 tosylate
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C21H19F4N7 · C7H8O3S
化学文摘社编号:
分子量:
617.62
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
FC(F)(F)c2c(ccc(c2)c3nc([n](c3)C)C4CCN(CC4)c5ncnc6n[nH]cc65)F.[S](=O)(=O)(O)c1ccc(cc1)C
InChI
1S/C21H19F4N7.C7H8O3S/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20;1-6-2-4-7(5-3-6)11(8,9)10/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30);2-5H,1H3,(H,8,9,10)
InChI key
HDYUXDNMHBQKAU-UHFFFAOYSA-N
Biochem/physiol Actions
LY2584702 is an orally active, ATP-competitive, potent and selective ribosomal protein S6 kinase (p70 S6 kinase, p70S6K, S6K1) inhibitor (IC50 = 4 nM; selective over 83 other kinases and 45 cell surface markers). LY2584702 inhibits HCT116 cellular S6 phosphorylation (IC50 0.1-0.24 μM) and shows anti-tumor efficacy in U87MG glioblastoma and HCT116 colon carcinoma xenograft models in vivo (2.5 mg/kg bid. po.).
Orally active, ATP-competitive, potent and selective ribosomal protein S6 kinase (p70 S6 kinase, p70S6K, S6K1) inhibitor with in vivo anti-tumor efficacy.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ming-Zhao Gao et al.
Acta pharmacologica Sinica, 40(2), 268-278 (2018-05-20)
BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma; however, most patients develop resistance, which limits the clinical benefit of these agents. In this study, we found that the human melanoma cell clones, A375-DR and A375-TR, with
Valentina Romeo et al.
Journal of immunology (Baltimore, Md. : 1950), 203(1), 137-147 (2019-05-17)
PI3K is one of the most frequently mutated genes in cancers and has been the target of numerous anticancer therapies. With the additional development of therapeutics that mobilize the immune system, such as Abs with effector functions, bispecific Abs, and
Honyin Chiu et al.
Journal of immunology (Baltimore, Md. : 1950), 202(2), 579-590 (2018-12-12)
During an adaptive immune response, activated mature B cells give rise to Ab-secreting plasma cells to fight infection. B cells undergo Ab class switching to produce different classes of Abs with varying effector functions. The mammalian/mechanistic target of rapamycin (mTOR)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2892-5MG | 04061842590766 |
| SML2892-25MG | 04061842590759 |